Dokument: Recreational cannabis use is the driving factor for participation in medical cannabis trials in inflammatory rheumatic diseases
| Titel: | Recreational cannabis use is the driving factor for participation in medical cannabis trials in inflammatory rheumatic diseases | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=71901 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20260115-114543-0 | |||||||
| Kollektion: | Publikationen | |||||||
| Sprache: | Englisch | |||||||
| Dokumententyp: | Wissenschaftliche Texte » Artikel, Aufsatz | |||||||
| Medientyp: | Text | |||||||
| Autoren: | Richter, Jutta [Autor] Beichert, Aurelia [Autor] Filla, Tim [Autor] Chehab, Gamal [Autor] Distler, Jörg H.W. [Autor] Schneider, Matthias [Autor] Frohne, Inna [Autor] Sert, D. [Autor] Aslandag, M. [Autor] | |||||||
| Dateien: |
| |||||||
| Stichwörter: | Medical cannabis , Inflammatory rheumatic disease , Herbal drugs , Recreational cannabis use , Chatbot-based survey , Clinical trial , Pain | |||||||
| Beschreibung: | Background
Though medical cannabis (MC) may have a role in the treatment of pain and anti-inflammation in patients with inflammatory rheumatic diseases (IRD), evidence and data are rare. We evaluated IRD patients’ attitudes towards the setting of a clinical trial (CT) with MC as prerequisites for the design of a prospective study in phytopharmacological translational research. Material and Methods A survey was conducted using the innovative Chatbot app Asepha enabling patient-centered data collection. Data collected included sociodemographic and disease-related information, current pain levels, treatment satisfaction, health status, and knowledge about MC. Patients’ willingness to participate in a MC CT and their concerns (e.g.fear of side effects/dependence) were assessed. Feasibility of Chatbot use was evaluated. R was used for data analyses. Results 250 IRD patients (67% female) were included. Despite high medication satisfaction (85%), more than one third was interested in MC CT participation, and additional 41% were potentially interested. Patients with previous recreational cannabis use were more likely to participate in a MC CT (OR 1.89). Furthermore, limitations in daily activities (OR 1.08), and bDMARD therapy (OR 1.43) increase the willingness. Lack of sufficient information about cannabis (67%), fear of side effects (40%) and dependence on cannabis (31%) are limiting factors for CT participation. Conclusion Chatbot use is feasible in phytopharmacological research. Three-quarter of our patients reported some interest in MC CT. Relevant predictors of interest were identified, with a history of cannabis use being the strongest. Understanding and controlling confounders seems crucial for successful planning and conduction of patient-centered future clinical trials in phytomedicine. | |||||||
| Rechtliche Vermerke: | Originalveröffentlichung:
Richter, J., Beichert, A., Filla, T., Chehab, G., Sert, D., Aslandag, M., Distler, J., Schneider, M., & Frohne, I. (2025). Recreational cannabis use is the driving factor for participation in medical cannabis trials in inflammatory rheumatic diseases. Phytomedicine, 150, Article 157599. https://doi.org/10.1016/j.phymed.2025.157599 | |||||||
| Lizenz: |  Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät | |||||||
| Dokument erstellt am: | 15.01.2026 | |||||||
| Dateien geändert am: | 15.01.2026 |
